CYTR - CytRx Corporation
| Previous Close | 0.3080 |
| Open | 0.2900 |
| Bid | 0.0000 x 1100 |
| Ask | 0.0000 x 1000 |
| Day's Range | 0.2810 - 0.3100 |
| 52 Week Range | 0.2100 - 0.7800 |
| Volume | 14,068 |
| Avg. Volume | 41,125 |
| Market Cap | 9.755M |
| Beta (3Y Monthly) | 1.87 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1960 |
| Earnings Date | Nov 9, 2018 - Nov 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.50 |
- PR Newswire
CytRx Corporation Reports Second Quarter 2019 Financial Results
Licensee Orphazyme A/S Rapidly Completes Enrollment in Clinical Trials for Multiple Indications and Prepares for Regulatory Submissions LOS ANGELES , Aug. 9, 2019 /PRNewswire/ -- CytRx Corporation (OTCQB: ...
- PR Newswire
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Prepares for Regulatory Filing of Arimoclomol in U.S. for Niemann-Pick Disease Type C
LOS ANGELES, July 30, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology and rare diseases, today highlighted that following a positive meeting with the U.S. Food and Drug Administration (FDA), arimoclomol licensee Orphazyme A/S (ORPH.CO) remains on track to submit a New Drug Application (NDA) for arimoclomol in Niemann-Pick Disease Type C (NPC) in the first half of 2020. Orphazyme also announced plans to introduce an Early Access Program for NPC in the fall of 2019.
- PR Newswire
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Completes Enrollment in its Phase 3 Clinical Trial of Arimoclomol in Amyotrophic Lateral Sclerosis
LOS ANGELES, July 22, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that arimoclomol licensee Orphazyme A/S (ORPH.CO) has completed enrollment in its Phase 3 clinical trial evaluating arimoclomol for the treatment of amyotrophic lateral sclerosis (ALS) ahead of schedule. The Phase 3 trial of arimoclomol for ALS is a 76-week, randomized, placebo-controlled trial being conducted at 30 centers of excellence in North America and Europe.
- ACCESSWIRE
CytRx Corporation Discusses Near Term Value from Out-License Deals and Growth Drivers for 2019 in New SNNLive Video Interview on StockNewsNow.com
LOS ANGELES, CA / ACCESSWIRE / June 27, 2019 / StockNewsNow.com , The Official MicroCap News Source™, today published an SNNLive Video Interview with Eric L. Curtis, President and COO of CytRx Corporation ...
- PR Newswire
CytRx Corporation Highlights Patent Issued for New Aldoxorubicin Formulation
Patent Covers the Formulation, Storage, Delivery and Administration of Aldoxorubicin at Room Temperature and Eliminates the Need for Cold Handling LOS ANGELES , June 26, 2019 /PRNewswire/ -- CytRx Corporation ...
- PR Newswire
CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S to Prepare Regulatory Submission in Europe for Niemann-Pick Disease Type C
LOS ANGELES, June 19, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing principally in oncology, today highlighted that arimoclomol licensee Orphazyme A/S (ORPH.CO) has updated the anticipated timing for submission of its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) seeking approval for arimoclomol in Niemann-Pick disease Type C (NPC). Based on advice received from the EMA's Scientific Advice Working Group, Orphazyme expects to submit the arimoclomol MAA in the first half of 2020.
- PR Newswire
CytRx Corporation to Commence Trading on OTCQB Venture Market
LOS ANGELES, May 31, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will commence trading on the OTCQB Venture Market as of Tuesday, June 4, 2019, under the same ticker symbol "CYTR". Investors can find current financial disclosure and real-time Level 2 quotes for the Company on www.otcmarkets.com/stock/CYTR/quote.
- Associated Press
CytRx: 1Q Earnings Snapshot
The Los Angeles-based company said it had a loss of 4 cents per share. Losses, adjusted to account for discontinued operations, were 5 cents per share. The company's shares closed at 52 cents. A year ago, ...
- PR Newswire
CytRx Corporation Reports First Quarter 2019 Financial Results
Out-licensed Assets Aldoxorubicin and Arimoclomol Rapidly Advancing into Multiple Indications of High Unmet Need CytRx Stands to Receive Significant Future Milestone Payments and Royalties from Licensing ...
- PR Newswire
CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer
"We are continually impressed with the progress that our partner and licensee NantCell has made with advancing aldoxorubicin in high unmet need oncology indications," said Eric Curtis, CytRx's President and Chief Operating Officer.
- PR Newswire
CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided by Licensee Orphazyme A/S
CytRx Eligible to Receive up to $120 Million in Future Milestones, Plus Royalties, From Arimoclomol Licensing Agreement LOS ANGELES , May 2, 2019 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical ...
- PR Newswire
CytRx Corporation Highlights Enrollment Completion in Phase 2/3 Clinical Trial of Sporadic Inclusion Body Myositis Conducted by Arimoclomol Licensee Orphazyme A/S
CytRx Eligible to Receive up to $120 Million in Future Milestones, Plus Royalties, From Arimoclomol Licensing Agreement LOS ANGELES , April 29, 2019 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a ...
- PR Newswire
CytRx Corporation Reports 2018 Financial Results
LADR™ Assets Well Aligned with Current Oncology Trends, Including Need for Improved Drugs and Potential for Combination with Immunotherapy Out-licensed Assets Aldoxorubicin and Arimoclomol with Strategic ...
- PR Newswire
CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could Be The First To Personalize Medicine For Albumin-Based Drug Delivery Systems
LOS ANGELES, March 12, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology treatment and diagnostics, and its private, wholly-owned subsidiary Centurion BioPharma Corporation, today announced the publication of peer reviewed, scientific research for its Albumin Companion Diagnostic (ACDx). The article, titled "Development of a Novel Imaging Agent for Determining Albumin Uptake in Solid Tumors," has been published online in Nuclear Medicine and Molecular Imaging. The abstract may be found and the full article purchased online at https://doi.org/10.1007/s13139-019-00587-w.
- PR Newswire
CytRx Corporation Leads Revival of Cytotoxic Therapies with LADR™ Technology Targeting Delivery Directly to the Tumor
LOS ANGELES, Feb. 13, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, and its private, wholly-owned subsidiary Centurion BioPharma Corporation, today announced the publication of peer reviewed, scientific research for LADR-7 (AE-Keto-Sulf07), one of its lead LADR™ (Linker Activated Drug Release) candidates. The article, entitled "Novel auristatin E-based albumin-binding prodrugs with superior anticancer efficacy in vivo compared to the parent compound" to be published in the Journal of Controlled Release, a leading journal for drug delivery on February 28, 2019. The abstract may be found and full article purchased online at https://www.sciencedirect.com/journal/journal-of-controlled-release/vol/296.
- PR Newswire
CytRx Corporation Highlights Majority of Cancer Patients Do Not Have Targetable Genetic Mutations and Are Therefore Candidates for Chemotherapy
LOS ANGELES, Feb. 11, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted comments from an OncLive® article dated February 1, 2019 that an estimated majority of oncology patients do not have targetable genetic mutations that would make them eligible for targeted treatment.
- PR Newswire
CytRx Corporation Highlights Positive Results from Full Data Set of Phase 2/3 Clinical Trial in Niemann Pick Disease Type C (NPC) Conducted by Arimoclomol Licensee Orphazyme A/S
LOS ANGELES, Feb. 6, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, highlighted positive Phase 2/3 clinical trial data from arimoclomol licensee Orphazyme A/S (ORPHA.CO). Orphazyme is currently developing arimoclomol in four different indications, including amyotrophic lateral sclerosis (ALS), Niemann-Pick disease Type C (NPC), Gaucher disease and sporadic Inclusion Body Myositis (sIBM).
- PR Newswire
CytRx Corporation Highlights Aldoxorubicin's Inclusion In New NantCell Inc. Colorectal Cancer Clinical Trial
LOS ANGELES, Jan. 14, 2019 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that aldoxorubicin licensee NantCell, Inc., a private subsidiary of NantWorks, LLC, has dosed the first patient in the Phase 1b portion of a Phase 1b/2 clinical trial for patients with relapsed or refractory colorectal cancer (CRC) who have been previously treated with standard of care (SOC) therapy. This is the fourth trial conducted by NantCell which will investigate high-affinity natural killer (haNK) cell therapy in combination with anti-cancer agents, including aldoxorubicin, in certain high unmet need cancer indications.
- PR Newswire
CytRx Corporation Announces Conclusion of Pre-Clinical Phase for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates and Accompanying Companion Diagnostic
LOS ANGELES, Dec. 21, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that its private, wholly-owned subsidiary Centurion BioPharma Corporation (the Company) has concluded the pre-clinical phase of its development for its albumin binding ultra high potency LADR™ (Linker Activated Drug Release) drug candidates, LADR-7, LADR-8, LADR-9 and LADR-10, and for its unique albumin companion diagnostic (ACDx). As a result of completing this work, operations taking place at the pre-clinical laboratory located in Freiburg, Germany will no longer be needed. The LADR™ platform combines Centurion's proprietary linker chemistry with albumin biology to create anti-cancer molecules that the Company believes will deliver highly potent agents directly to the tumor, while avoiding unacceptable systemic toxicity. The pre-clinical laboratory synthesized and evaluated over 75 rationally-designed drug conjugates across two distinct classes of compounds, the auristatins and maytansinoids.